Exhibit 99.1



ProPhase Labs Reports Financial Results

for the Year Ended December 31, 2018


DOYLESTOWN, Pennsylvania – March 26, 2019. 

ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today reported its net sales from continuing operations were $13.1 million for the year ended December 31, 2018, as compared to net sales of $9.9 million for the year ended December 31, 2017. The Company realized a net loss for the year ended December 31, 2018 of $1.7 million compared to a net income of $40.6 million for the year ended December 31, 2017.


The Company realized loss from continuing operations for the year ended December 31, 2018, of $1.6 million, or ($0.14) per share, as compared to a loss of $2.2 million, or ($0.14) per share, for the year ended December 31, 2017. The Company realized loss from discontinued operations for the year ended December 31, 2018, of $170,000, or ($0.01) per share, as compared to income of $42.8 million, or $2.75 per share, for the year ended December 31, 2017.


As previously announced, effective March 29, 2017 and with the approval of the Company’s stockholders, the Company completed the sale of assets comprised principally of the sale of intellectual property rights and other assets relating to the Cold-EEZE® brand and product line (collectively, referred to herein as the “Cold-EEZE® Business”) to a wholly-owned subsidiary of Mylan N.V. (“Mylan”). As a consequence of the sale of the Cold-EEZE® Business, for the years ended December 31, 2018 and 2017, the Company has classified as discontinued operations the (i) gain from the sale of the Cold-EEZE® Business, (ii) all gains and losses attributable to the Cold-EEZE® Business and (iii) the income tax expense attributed to the sale of the Cold-EEZE® Business.


We continue to own and operate our manufacturing facility and manufacturing business in Lebanon, Pennsylvania, and our headquarters in Doylestown, Pennsylvania. As part of the sale of the Cold-EEZE® Business, we entered into a manufacturing agreement to supply various Cold-EEZE® lozenge products to Mylan. In addition, we produce over-the-counter drug and dietary supplement lozenges and other products for other third party customers. We are also pursuing a series of new product development and commercialization initiatives in the dietary supplement category.




Ted Karkus, the CEO of the Company, stated: “It continues to be our goal to optimize the long term value of our company’s shares.  In 2017, to provide enhanced liquidity to our shareholders we conducted two self-tenders and enabled our shareholders to sell back just over 6 million shares of Company common stock.  In 2018, we provided a one-time special dividend of $1.00 per share to all of our shareholders.  More recently, we followed this up with an additional one-time special dividend of $0.25 per share.  In short, the ProPhase management team continues to return great value to our shareholders.”


Mr. Karkus continued, “We are on track with the development of ProPhase Digital Media (“PDM”), the digital marketing division of the Company. We recently completed the optimization phase for digital distribution of our lead product, Legendz XL®. We expect to ramp up direct to consumer sales of Legendz XL® during 2019.  If our model proves successful, our goal is for PDM to market our other internally developed products and ultimately market other companies’ products as well.”


Mr. Karkus added, “In addition to digital distribution, we continue to ship our new dietary supplement, Legendz XL®, to a major retail drug chain and other retailers.  We currently have positive indications of interest from other major retailers as well.  Implementation of our dietary supplement strategy will require significant investment in marketing as well as significant additional distribution within the various retail channels and e-commerce venues in order to achieve a successful launch and build a successful new product line.”


Mr. Karkus also noted, “We continue to own and operate our Pharmaloz manufacturing facility which manufactures and supplies Cold-EEZE® lozenges to Mylan as well as lozenges to other companies on a contract manufacturing basis. Manufacturing revenue fluctuates from quarter to quarter.  Also, marketing and distribution expenses may increase as we build our consumer products businesses.  Therefore, the Company’s results are likely to continue to fluctuate from quarter to quarter.”


Mr. Karkus concluded, “Looking forward, in addition to developing our consumer products businesses and growing our manufacturing business, the Company continues to explore a wide range of acquisition opportunities in the consumer products space, as well as investments and acquisitions in other sectors and industries.”


About the Company


We are a vertically integrated and diversified branding, marketing and technology company with deep experience with over-the-counter (“OTC”) consumer healthcare products, dietary supplements and other remedies. We are engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products, dietary supplements and other remedies in the United States.  This includes the development and marketing of dietary supplements under the TK Supplements® brand, a wholly-owned subsidiary of the Company.


In addition, the Company also continues to actively pursue acquisition opportunities for other companies, technologies and products inside and outside the consumer products industry. For more information visit us at www.ProPhaseLabs.com.




Forward Looking Statements


Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of our new line of TK Supplements®, our new product Legendz XL® and the formation of ProPhase Digital Media. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the difficulty of predicting the acceptance and demand for our products, the impact of competitive products and pricing, costs involved in the manufacture and marketing of products, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.


Investor Contact


Ted Karkus, Chairman and CEO

ProPhase Labs, Inc.

(267) 880-1111






(in thousands, except per share amounts)


    Year Ended December 31,  
    2018     2017  
Net sales   $ 13,126     $ 9,867  
Cost of sales     8,345       7,919  
Gross profit     4,781       1,948  
Operating expenses                
Sales and marketing     1,107       699  
Administration     4,910       4,808  
Research and development     398       431  
Total operating expenses     6,415       5,938  
Interest income, net     167       177  
Other income     -       150  
Total interest and other income     167       327  
Loss from continuing operations before income taxes     (1,467 )     (3,663 )
Income tax benefit (provision) from continuing operations     (103 )     1,421  
Loss from continuing operations     (1,570 )     (2,242 )
Discontinued operations:                
Income from discontinued operations     -       530  
Gain (loss) on sale of discontinued operations, net of taxes     (170 )     42,301  
Income (loss) from discontinued operations     (170 )     42,831  
Net income (loss)   $  (1,740 )   $ 40,589  
Other comprehensive income (loss):                
Unrealized gain loss on marketable securities     54       (78 )
Total comprehensive income (loss)     (1,686 )     40,511  
Basic earnings (loss) per share:                
Loss from continuing operations   $ (0.14 )   $ (0.14 )
Income (loss) from discontinued operations     (0.01 )     2.75  
Net income (loss)   $ (0.15 )   $ 2.61  
Diluted earnings (loss) per share:                
Loss from continuing operations   $  (0.14 )   $ (0.14 )
Income (loss) from discontinued operations     (0.01 )     2.73  
Net income (loss)   $ (0.15 )   $ 2.59  
Weighted average common shares outstanding:                
Basic     11,396       15,565  
Diluted     11,396       15,696  






(in thousands)


    December 31 2018     December 31 2017  
Cash and cash equivalents   $ 1,554     $ 3,173  
Marketable securities, available for sale   $ 6,687     $ 18,765  
Accounts receivable, net   $ 2,968     $ 1,945  
Inventory   $ 1,903     $ 1,531  
Total current assets   $ 18,238     $ 28,417  
Total assets   $ 20,737     $ 33,659  
Total current liabilities   $ 4,233     $ 1,812  
Total stockholders’ equity   $ 16,504     $ 31,847  






The following information was filed by Prophase Labs, Inc. (PRPH) on Tuesday, March 26, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Prophase Labs, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Prophase Labs, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account